Which GLP-1 is FDA-approved for weight loss in women?

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults, women included, based on BMI. Ozempic and Mounjaro are the same molecules approved for type 2 diabetes, so their weight use is off-label.

Do GLP-1 drugs affect birth control?

The tirzepatide label (Zepbound, Mounjaro) warns it may reduce oral-contraceptive effectiveness and advises a non-oral or backup barrier method for 4 weeks after starting and after each dose increase. The semaglutide label (Wegovy, Ozempic) does not carry this warning.

Can I take a GLP-1 while pregnant or breastfeeding?

No. The labels advise discontinuing before a planned pregnancy, and for semaglutide that means stopping at least 2 months ahead because of its long half-life. GLP-1 drugs are not recommended during pregnancy or breastfeeding. Confirm timing with your clinician.

Are GLP-1 drugs approved for PCOS?

No GLP-1 drug is FDA-approved specifically for PCOS. The 2023 International PCOS Guideline recognizes anti-obesity medications as an adjunct where weight management is a treatment goal, so any PCOS use is off-label and clinician-directed.

Is there a GLP-1 patch or a cheap compounded version?

There is no FDA-approved GLP-1 patch, and compounded semaglutide and tirzepatide became restricted after the FDA resolved the shortages in 2024-2025. The FDA has warned about unapproved and counterfeit products, so approved options prescribed by a clinician are safer.

Editorial molecule guide · Updated July 2026

GLP-1 for Women: Molecule Guide, Cost and Cautions

Medically reviewed by Editorial Medical Review, MD, NAMS-CMP. This is an educational explainer, not a ranked provider list.

Quick answer

GLP-1 medications help with weight and blood sugar by mimicking gut hormones that reduce appetite. For women, the FDA-approved weight options are Wegovy (semaglutide) and Zepbound (tirzepatide); Ozempic and Mounjaro are the same molecules approved for type 2 diabetes. Tirzepatide, but not semaglutide, carries an oral-contraceptive warning.

GLP-1 receptor agonists have become a leading option for weight management, and women often have specific questions that generic drug pages do not answer: how each option interacts with pregnancy planning and birth control, whether it can be used for PCOS or perimenopausal weight gain, and what it actually costs. This guide summarizes each molecule from that angle and links to the FDA labels, published trials, and pricing sources behind every claim. It does not rank providers or recommend a specific treatment.

GLP-1 options at a glance

Women-angle decision framing with cited cost ranges. For the FDA-verbatim efficacy and safety numbers side by side, see our clinical comparison of semaglutide vs tirzepatide.

Cost ranges are cited per row; verify current pricing on the manufacturer page before acting.
Brand	Molecule	FDA status for weight	Delivery	Women-specific note	Monthly cost (cited)
Wegovy	Semaglutide 2.4 mg	FDA-approved for chronic weight management	Once-weekly injection (pen)	Stop 2 months before a planned pregnancy; no oral-contraceptive warning	$499 cash (NovoCare) to $1,349 list source ↗
Zepbound	Tirzepatide	FDA-approved for chronic weight management	Once-weekly injection (pen or vial)	May lower oral birth-control effectiveness; use backup for 4 weeks	$349-$599 cash (LillyDirect) to $1,086 list source ↗
Ozempic	Semaglutide	Not approved for weight (type 2 diabetes only; weight use off-label)	Once-weekly injection (pen)	Same pregnancy caution as Wegovy; weight use is off-label	~$935 list; insurer copay for diabetes source ↗
Mounjaro	Tirzepatide	Not approved for weight (type 2 diabetes only; weight use off-label)	Once-weekly injection (pen)	Same oral-contraceptive warning as Zepbound	~$1,086 list; insurer copay for diabetes source ↗
Compounded semaglutide / tirzepatide	Semaglutide or tirzepatide (pharmacy-mixed)	Not FDA-approved; availability restricted since 2024-2025	Injection prepared by a compounding pharmacy	Dose and purity not FDA-verified; approved options preferred	Historically $150-$400 cash; now limited source ↗

Which option fits your goal?

These are informational starting points based on FDA labels and published trials, not a treatment recommendation. A licensed clinician decides what is appropriate for you.

Largest average weight reduction in trials

Tirzepatide (Zepbound) showed up to about 20.9% mean weight loss in SURMOUNT-1, versus about 14.9% for semaglutide (Wegovy) in STEP 1. These are separate trials, not a head-to-head weight study, so a clinician should weigh the trade-offs. Read more

You take an oral contraceptive pill

The tirzepatide label (Zepbound, Mounjaro) warns of reduced oral-contraceptive effectiveness and advises a backup method; the semaglutide label (Wegovy, Ozempic) does not. If pill effectiveness is a priority, this label difference is worth raising with a clinician. Read more

You have type 2 diabetes, not just weight goals

Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes and are more likely to be insurance-covered for that diagnosis. Wegovy and Zepbound are the weight-approved versions of the same molecules. Read more

You prefer a pill over an injection

Rybelsus is a daily oral semaglutide tablet, but it is approved for type 2 diabetes, not weight. A higher-dose oral semaglutide for weight is under FDA review, so an approved oral weight-loss option may not yet exist when you read this. Read more

You saw a cheap compounded or patch option online

Compounded GLP-1 drugs are not FDA-approved and are now restricted, and there is no FDA-approved GLP-1 patch. The FDA has warned about unapproved and counterfeit products, so approved options prescribed by a clinician are the safer route. Read more

Molecule explainers

Wegovy for women

GLP-1 receptor agonist (semaglutide 2.4 mg)

Zepbound for women

GIP/GLP-1 receptor dual agonist (tirzepatide)

Ozempic for women

GLP-1 receptor agonist (semaglutide)

Oral semaglutide (Rybelsus) for women

Oral GLP-1 receptor agonist (semaglutide tablet)

Compounded semaglutide for women

Compounded GLP-1 receptor agonist (semaglutide)

Compounded tirzepatide for women

Compounded GIP/GLP-1 dual agonist (tirzepatide)

Retatrutide for women

GIP/GLP-1/glucagon receptor triple agonist (investigational)

GLP-1 patches

Unapproved transdermal delivery claim (no approved product)

Looking for providers who prescribe these?

This page is an explainer. To compare telehealth providers, use our provider directory and our 2026 editorial ranking. Prescribing decisions rest with a licensed clinician.

All GLP-1 for women providers — the full provider directory.
Best GLP-1 for women 2026 — our ranked editorial picks.

A few active providers we review (editorial reviews only, not treatment recommendations):

Form Health — Board-certified obesity medicine physicians prescribing GLP-1s. Often insurance-covered — among the most affordable options when insurance applies.
Knownwell — Weight-inclusive primary care with GLP-1 access. Designed by clinicians frustrated with typical obesity medicine model — focuses on the whole person.
Plushcare GLP-1 — Primary care telehealth that prescribes Wegovy and Zepbound when clinically appropriate. Insurance-friendly.
Calibrate (Insurance) — Calibrate’s insurance-billing arm for women whose employer plan covers Wegovy or Zepbound.
Noom Med — Noom’s GLP-1 telehealth arm pairing semaglutide/tirzepatide prescribing with behavior-change coaching.
Hers (Weight Loss) — Hims & Hers' weight loss division offering compounded GLP-1s plus FDA-approved options. Among the most affordable starting prices.

Full cost guides and related topics

Frequently asked questions

Which GLP-1 is FDA-approved for weight loss in women?: Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in adults, women included, based on BMI. Ozempic and Mounjaro are the same molecules approved for type 2 diabetes, so their weight use is off-label.
Do GLP-1 drugs affect birth control?: The tirzepatide label (Zepbound, Mounjaro) warns it may reduce oral-contraceptive effectiveness and advises a non-oral or backup barrier method for 4 weeks after starting and after each dose increase. The semaglutide label (Wegovy, Ozempic) does not carry this warning.
Can I take a GLP-1 while pregnant or breastfeeding?: No. The labels advise discontinuing before a planned pregnancy, and for semaglutide that means stopping at least 2 months ahead because of its long half-life. GLP-1 drugs are not recommended during pregnancy or breastfeeding. Confirm timing with your clinician.
Are GLP-1 drugs approved for PCOS?: No GLP-1 drug is FDA-approved specifically for PCOS. The 2023 International PCOS Guideline recognizes anti-obesity medications as an adjunct where weight management is a treatment goal, so any PCOS use is off-label and clinician-directed.
Is there a GLP-1 patch or a cheap compounded version?: There is no FDA-approved GLP-1 patch, and compounded semaglutide and tirzepatide became restricted after the FDA resolved the shortages in 2024-2025. The FDA has warned about unapproved and counterfeit products, so approved options prescribed by a clinician are safer.

ClearHormones publishes editorial drug research and updates it as FDA status and pricing change. Verify current approval status and pricing on the manufacturer or FDA page before acting.